UA94693C2 - Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease - Google Patents

Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Info

Publication number
UA94693C2
UA94693C2 UAA200611798A UAA200611798A UA94693C2 UA 94693 C2 UA94693 C2 UA 94693C2 UA A200611798 A UAA200611798 A UA A200611798A UA A200611798 A UAA200611798 A UA A200611798A UA 94693 C2 UA94693 C2 UA 94693C2
Authority
UA
Ukraine
Prior art keywords
patients
fatty acids
epa
essential fatty
depression
Prior art date
Application number
UAA200611798A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Сеес-Нико Вербоом
Райнер Ольце
Original Assignee
Солвей Фармасьютикалс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Гмбх filed Critical Солвей Фармасьютикалс Гмбх
Publication of UA94693C2 publication Critical patent/UA94693C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for preventing and/or treating depression in patients with cardiovascular disease comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a high content in eicosapentanoic acid ethyl ester (EPA), in docosahexaenoic acid ethyl ester (DHA) or in a high concentration mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), wherein the EPA/DHA ratio by weight in the EPA and DHA mixture is about 0.9 to 1.5.
UAA200611798A 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease UA94693C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04101578 2004-04-16

Publications (1)

Publication Number Publication Date
UA94693C2 true UA94693C2 (en) 2011-06-10

Family

ID=34928968

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200611798A UA94693C2 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Country Status (12)

Country Link
EP (1) EP1765319A1 (en)
JP (1) JP2007532605A (en)
CN (1) CN1942180A (en)
AU (1) AU2005244483B2 (en)
BR (1) BRPI0509878A (en)
CA (1) CA2504280A1 (en)
IL (1) IL178300A0 (en)
MX (1) MX291518B (en)
RU (1) RU2387448C2 (en)
UA (1) UA94693C2 (en)
WO (1) WO2005110393A1 (en)
ZA (1) ZA200607794B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
ITMI20100961A1 (en) * 2010-05-27 2011-11-28 Erredue Spa MIXTURES RICH IN OMEGA-3 FATTY ACIDS, THEIR COMPOSITIONS AND THEIR PREPARATION PROCESS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
CA2449199A1 (en) * 2001-05-30 2002-12-05 Laxdale Limited Coenzyme q and eicosapentaenoic acid (epa)

Also Published As

Publication number Publication date
JP2007532605A (en) 2007-11-15
CN1942180A (en) 2007-04-04
MXPA06011940A (en) 2006-12-15
AU2005244483B2 (en) 2011-06-09
AU2005244483A1 (en) 2005-11-24
ZA200607794B (en) 2008-05-28
RU2006140277A (en) 2008-05-27
RU2387448C2 (en) 2010-04-27
CA2504280A1 (en) 2005-10-16
BRPI0509878A (en) 2007-10-16
WO2005110393A1 (en) 2005-11-24
MX291518B (en) 2011-10-31
EP1765319A1 (en) 2007-03-28
IL178300A0 (en) 2007-02-11

Similar Documents

Publication Publication Date Title
CN1198608C (en) Therapeutic and dietary compsns. containing essential fatty acids and bioactive disulphides
Singer et al. Slow desaturation and elongation of linoleic and α-linolenic acids as a rationale of eicosapentaenoic acid-rich diet to lower blood pressure and serum lipids in normal, hypertensive and hyperlipemic subjects
US5618558A (en) Fatty acid treatment
US5198468A (en) Essential fatty acid composition
US5116624A (en) Efa compositions and therapy
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
HUP0303019A2 (en) Use of pharmaceutical compositions containing essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
DE60000133D1 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS
BRPI0408006A (en) use of omega-3 fatty acids in the treatment of diabetic patients
BRPI0518398A2 (en) Omega-3 Fatty Acids and Delipidemic Agent for Lipid Therapy
SK14502003A3 (en) Coenzyme Q and eicosapentaenoic acid
KR20000049016A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
WO2003072111A3 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
WO2008018043A3 (en) Methods of improving bone health and muscle health
WO2002064148A3 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
IE921806A1 (en) Fatty acid treatment
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
IE860516L (en) Treatment of prostatic hypertrophy
UA94693C2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
US20100239660A1 (en) Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions
Eritsland et al. Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile
McCarty High-chromium yeast for acne?
UA79650C2 (en) Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy
JPWO2023004151A5 (en)
RU99106551A (en) APPLICATION OF ARAHIDONIC ACID AND / OR DOCOSAHEXAICAENIC ACID FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF DYSPRAXIA